60 DEGREES PHARMACEUTICALS INC
For the period ended Mar 31, 2024. Filed May 15, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 15, 2024
SXTP$0.52-4.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Condensed Statements of Operations and Comprehensive Loss
CONSOLIDATED CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (UNAUDITED)
| For The Three Months Ended March 31, | 2024 | 2023 |
|---|---|---|
| Product Revenues – net of Discounts and Rebates | $105,674 | $17,172 |
| Service Revenues | 10,789 | - |
| Product and Service Revenues, net | 116,463 | 17,172 |
| Cost of Revenues | 65,437 | 73,120 |
| Gross Profit (Loss) | 51,026 | (55,948) |
| Research Revenues | 29,631 | 4,292 |
| Net Revenue (Loss) | 80,657 | (51,656) |
| Operating Expenses | ||
| Research and Development | 337,182 | 123,994 |
| General and Administrative Expenses | 1,075,134 | 775,014 |
| Total Operating Expenses | 1,412,316 | 899,008 |
| Loss from Operations | (1,331,659) | (950,664) |
| Interest Expense | (1,402) | (1,141,429) |
| Change in Fair Value of Derivative Liabilities | 1,740,847 | (5,134) |
| Loss on Debt Extinguishment | - | (839,887) |
| Change in Fair Value of Promissory Note | - | 339,052 |
| Other Income | 20,262 | 591 |
| Total Interest and Other Income (Expense), net | 1,759,707 | (1,646,807) |
| Net Income (Loss) before Provision for Income Taxes | 428,048 | (2,597,471) |
| Provision for Income Taxes (Note 9) | 63 | 63 |
| Net Income (Loss) including Noncontrolling Interest | 427,985 | (2,597,534) |
| Net (Loss) Gain – Noncontrolling Interest | (2,485) | 2,527 |
| Net Income (Loss) – attributed to 60 Degrees Pharmaceuticals, Inc. | 430,470 | (2,600,061) |
| Comprehensive Income (Loss): | ||
| Net Income (Loss) | 427,985 | (2,597,534) |
| Unrealized Foreign Currency Translation Loss | (3,894) | (1,290) |
| Total Comprehensive Income (Loss) | 424,091 | (2,598,824) |
| Net (Loss) Gain – Noncontrolling Interest | (2,485) | 2,527 |
| Comprehensive Income (Loss) – attributed to 60 Degrees Pharmaceuticals, Inc. | 426,576 | (2,601,351) |
| Cumulative Dividends on Series A Preferred Stock | (117,881) | - |
| Net Income (Loss) - attributed to Common Stockholders | $308,695 | $(2,601,351) |
| Net Income (Loss) per Common Share | ||
| Basic and Diluted | $0.03 | $(1.13) |
| Weighted Average Number of Common Shares Outstanding | ||
| Basic and Diluted | 10,124,517 | 2,304,131 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.